Texas Everlasting College Fund Corp trimmed its place in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 17.3% in the course of the second quarter, in line with its most up-to-date Type 13F submitting with the Securities & Trade Fee. The institutional investor owned 65,899 shares of the medical system firm’s inventory after promoting 13,795 shares in the course of the interval. Texas Everlasting College Fund Corp’s holdings in DexCom had been value $7,472,000 as of its most up-to-date SEC submitting.
Different massive traders additionally not too long ago added to or decreased their stakes within the firm. Vanguard Group Inc. raised its stake in shares of DexCom by 0.3% within the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical system firm’s inventory valued at $6,186,539,000 after buying an extra 136,282 shares within the final quarter. Capital Analysis International Traders raised its stake in shares of DexCom by 21.4% within the fourth quarter. Capital Analysis International Traders now owns 15,296,032 shares of the medical system firm’s inventory valued at $1,898,085,000 after buying an extra 2,695,296 shares within the final quarter. Sands Capital Administration LLC raised its stake in shares of DexCom by 10.2% within the fourth quarter. Sands Capital Administration LLC now owns 15,058,806 shares of the medical system firm’s inventory valued at $1,868,647,000 after buying an extra 1,398,136 shares within the final quarter. Capital World Traders raised its stake in shares of DexCom by 130.7% within the fourth quarter. Capital World Traders now owns 9,278,685 shares of the medical system firm’s inventory valued at $1,151,392,000 after buying an extra 5,256,092 shares within the final quarter. Lastly, Artisan Companions Restricted Partnership raised its stake in shares of DexCom by 164.8% within the fourth quarter. Artisan Companions Restricted Partnership now owns 5,900,308 shares of the medical system firm’s inventory valued at $732,169,000 after buying an extra 3,672,471 shares within the final quarter. 97.75% of the inventory is at present owned by institutional traders and hedge funds.
DexCom Inventory Efficiency
Shares of DXCM inventory opened at $68.55 on Wednesday. The inventory’s 50-day shifting common is $84.93 and its two-hundred day shifting common is $112.21. The agency has a market cap of $27.47 billion, a price-to-earnings ratio of 44.23, a PEG ratio of two.12 and a beta of 1.18. DexCom, Inc. has a 1 yr low of $62.34 and a 1 yr excessive of $142.00. The corporate has a debt-to-equity ratio of 1.00, a fast ratio of two.48 and a present ratio of two.82.
DexCom (NASDAQ:DXCM – Get Free Report) final issued its quarterly earnings knowledge on Thursday, July twenty fifth. The medical system firm reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on fairness of 31.41% and a internet margin of 16.95%. The corporate had income of $1 billion for the quarter, in comparison with analyst estimates of $1.04 billion. Throughout the identical quarter final yr, the corporate posted $0.34 earnings per share. The enterprise’s quarterly income was up 15.3% in comparison with the identical quarter final yr. Analysts predict that DexCom, Inc. will submit 1.69 earnings per share for the present yr.
Analyst Scores Adjustments
DXCM has been the subject of a number of analyst reviews. Stifel Nicolaus elevated their value goal on DexCom from $90.00 to $100.00 and gave the corporate a “purchase” ranking in a analysis observe on Friday, August twenty third. UBS Group dropped their goal value on DexCom from $163.00 to $95.00 and set a “purchase” ranking on the inventory in a report on Friday, July twenty sixth. Oppenheimer dropped their goal value on DexCom from $150.00 to $115.00 and set an “outperform” ranking on the inventory in a report on Friday, July twenty sixth. BTIG Analysis dropped their goal value on DexCom from $156.00 to $120.00 and set a “purchase” ranking on the inventory in a report on Friday, July twenty sixth. Lastly, Piper Sandler reissued an “obese” ranking and issued a $90.00 goal value on shares of DexCom in a report on Monday, August twenty sixth. Seven equities analysis analysts have rated the inventory with a maintain ranking, eleven have given a purchase ranking and one has given a powerful purchase ranking to the inventory. Primarily based on knowledge from MarketBeat, the corporate presently has a consensus ranking of “Reasonable Purchase” and a mean goal value of $112.25.
Test Out Our Newest Inventory Evaluation on DXCM
Insider Shopping for and Promoting
In associated information, EVP Michael Jon Brown bought 652 shares of the agency’s inventory in a transaction dated Wednesday, July thirty first. The inventory was bought at a mean value of $69.55, for a complete transaction of $45,346.60. Following the transaction, the manager vp now owns 66,249 shares of the corporate’s inventory, valued at $4,607,617.95. The transaction was disclosed in a submitting with the SEC, which is accessible by means of this hyperlink. In associated information, Director Bridgette P. Heller bought 1,000 shares of the agency’s inventory in a transaction dated Friday, June 14th. The shares had been bought at a mean value of $113.55, for a complete worth of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares within the firm, valued at $2,878,378.95. The sale was disclosed in a authorized submitting with the SEC, which is on the market by means of the SEC web site. Additionally, EVP Michael Jon Brown bought 652 shares of the agency’s inventory in a transaction dated Wednesday, July thirty first. The shares had been bought at a mean value of $69.55, for a complete transaction of $45,346.60. Following the completion of the sale, the manager vp now owns 66,249 shares of the corporate’s inventory, valued at roughly $4,607,617.95. The disclosure for this sale will be discovered right here. Insiders have bought a complete of two,311 shares of firm inventory valued at $234,214 during the last quarter. 0.30% of the inventory is at present owned by insiders.
About DexCom
DexCom, Inc, a medical system firm, focuses on the design, improvement, and commercialization of steady glucose monitoring (CGM) techniques in the USA and internationally. The corporate offers its techniques to be used by folks with diabetes, in addition to to be used by healthcare suppliers. Its merchandise embrace Dexcom G6 and Dexcom G7, built-in CGM techniques for diabetes administration; Dexcom Share, a distant monitoring system; Dexcom Actual-Time API, which allows licensed third-party software program builders to combine real-time CGM knowledge into their digital well being apps and units; and Dexcom ONE, that’s designed to interchange finger stick blood glucose testing for diabetes remedy selections.
Learn Extra
Wish to see what different hedge funds are holding DXCM? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Obtain Information & Scores for DexCom Day by day – Enter your electronic mail deal with beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for DexCom and associated corporations with MarketBeat.com’s FREE day by day electronic mail e-newsletter.
